---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030075"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:30:10.328454+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma FY2024 revenue $81M, adjusted EBITDA $9.2M; ADHD net revenue +23%

## Summary
- FY2024 consolidated net revenue $81.0M (down 25% YoY); net loss $15.8M ($2.86/share)
- Adjusted EBITDA improved to $9.2M from $3.5M ( +162%); Rx Business EBITDA $10.8M
- ADHD Portfolio net revenue +23% to $57.8M; Pediatric unit shipments up 115% since July 1
- Consumer Health Segment divested in July 2024; company expects Rx Segment revenue and EBITDA growth in FY2025
- Cash balance $20.0M; refinanced term loan; $3.5M from warrant exercises

## SEC filing metadata
- accession: 0001437749-24-030075
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774924030075/0001437749-24-030075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774924030075/aytu20240610_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030075
- JSON: https://secwatch.observer/filing/0001437749-24-030075.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.